News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

22nd Century Group, Inc. Announces U.S. Patent Issues for MPO Nicotine Biosynthesis Gene


4/3/2013 10:51:37 AM

CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction products, today announced that the United States Patent and Trademark Office (US PTO) has issued Patent No. 8,410,341 for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant. As previously announced, the US PTO issued a Notice of Allowance on December 24, 2012 for this technology; however, yesterday’s issuance marks the official grant of the patent.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES